U.K. Biotech Learns Lessons From History, Says BIA Head
This article was originally published in The Pink Sheet Daily
Executive Summary
Adversity has honed a solid foundation for U.K. biotech that might be better placed to resist cyclical changes in investor sentiment than the U.S., proposes the head of the U.K biotech industry association.
You may also be interested in...
Deal Watch: Roche Returns To RNAi With Santaris Buyout, While Biogen Re-Ups With Regulus
Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.